JPM26: Jazz sells PRV for $200m, targets deals in 2026 [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
Speaking at the JP Morgan Healthcare Conference 2026, held in San Francisco, US, from 12 to 15 January, CEO Renee Gala revealed that Jazz sold the voucher but did not disclose the buyer or the month the transaction took place. As per the presentation, half of the gross proceeds will go to Jazz. The US rare disease specialist ended Q3 2025 with more than $2bn in cash and investments. “We fully expect to announce one or two or more deals in 2026. We do aim to continue growing our business and optimising our future value through corporate development,” Gala said at the conference. Jazz gained the voucher upon US Food and Drug Administration (FDA) approval of Modeyso (dordaviprone) for the treatment of an aggressive type of brain tumour in August 2025. The company inherited the therapy during its acquisition of Chimerix for $935m last March. Gala expects more than $500m peak potential in revenue for Modeyso. PRVs, which reduce the FDA review time of a drug application from the usua
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors [Yahoo! Finance]Yahoo! Finance
- United Therapeutics (NASDAQ:UTHR) was given a new $645.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.MarketBeat
- United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- S&P 500 Futures Flat in Premarket Trading; United Therapeutics, Intel Lag [Barron's]Barrons
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 1/15/26 - Form 4
- 1/15/26 - Form 144
- 1/13/26 - Form 4
- UTHR's page on the SEC website